(Total Views: 208)
Posted On: 09/18/2020 10:51:17 AM
Post# of 36567
This quote from the PR kind of answers the Q on the peptide status:
"We have initiated the blood screening program using convalescent blood and serum for COVID-19 recovered patients to select Ii-Key-SARS-CoV-2 epitopes that will comprise the final vaccine formulation, after which we will initiate GMP manufacturing for Ii-Key-SARS-CoV-2 vaccine clinical trial supply."
So they are still in the process... hopefully this is conservative, and testing has taken place, but we couldn't pay for the results (which we should be able to do soon). Or the testing can start now, with Bintai picking up the tab. Either way, both parties have an interest in moving forward, so let's assume that is happening as soon as the final deal is signed.
Someone asked about the timing of the $17.5MM milestone payment. It seems to me that it is contingent upon a successful, tested vaccine that is approved for the population of Malaysia by their gov't, no?
"We have initiated the blood screening program using convalescent blood and serum for COVID-19 recovered patients to select Ii-Key-SARS-CoV-2 epitopes that will comprise the final vaccine formulation, after which we will initiate GMP manufacturing for Ii-Key-SARS-CoV-2 vaccine clinical trial supply."
So they are still in the process... hopefully this is conservative, and testing has taken place, but we couldn't pay for the results (which we should be able to do soon). Or the testing can start now, with Bintai picking up the tab. Either way, both parties have an interest in moving forward, so let's assume that is happening as soon as the final deal is signed.
Someone asked about the timing of the $17.5MM milestone payment. It seems to me that it is contingent upon a successful, tested vaccine that is approved for the population of Malaysia by their gov't, no?
(1)
(0)
